Nivolumab plus Platinum-doublet chemotherapy vs chemotherapy as first-line treatment for advanced non-small cell lung cancer with less than 1% tumor PD-L1 expression: CheckMate 227
CheckMate 227, a phase 3 study of first-line Nivolumab ( Opdivo ) plus Ipilimumab ( Yervoy ), Nivolumab, or Nivolumab plus chemotherapy vs chemotherapy in advanced non-small cell lung cancer ( NSCLC ), met its co-primary endpoint of prolonged progression-free survival ( PFS ) with Nivolumab plus Ipilimumab vs chemotherapy in patients with tumor mutational burden greater than or equal to 10 mutations/Mb.
Identifying effective treatment for patients without known predictive biomarkers remains an unmet need.
Prior studies suggest addition of chemotherapy to anti–PD-(L)1 treatment can improve outcomes in an unselected patient population, although benefit is most pronounced in patients with higher tumor PD-L1 expression.
Researchers have reported results for Nivolumab plus chemotherapy versus chemotherapy in patients with less than 1% tumor PD-L1 expression.
Patients ( n = 550 ) with chemotherapy-naive, stage IV/recurrent NSCLC, no known sensitizing EGFR/ALK mutations, and less than 1% tumor PD-L1 expression were stratified by tumor histology and randomized 1:1:1 to Nivolumab 3 mg/kg Q2W plus Ipilimumab 1 mg/kg Q6W, Nivolumab 360 mg Q3W plus chemotherapy, or chemotherapy ( optional Pemetrexed maintenance after chemotherapy for nonsquamous [ non-SQ ] NSCLC ).
Patients were treated up to 2 years.
A descriptive analysis was performed for the secondary endpoint of PFS for Nivolumab plus chemotherapy versus chemotherapy in patients with less than 1% tumor PD-L1 expression.
Baseline characteristics were balanced between Nivolumab plus chemotherapy ( n=177 ) and chemotherapy ( n=186 ) arms.
Progression-free survival was improved with Nivolumab plus chemotherapy vs chemotherapy ( hazard ratio, HR=0.74 [ 95% CI: 0.58, 0.94 ]; minimum follow-up 11.2 months; descriptive comparison ).
PFS benefit with Nivolumab plus chemotherapy was observed across most subgroups. Among histologic subgroups, benefit was more pronounced in non-SQ ( HR = 0.68 ) relative to SQ NSCLC ( HR = 0.92 ).
Rates of any grade treatment-related adverse events leading to discontinuation were 13% with Nivolumab plus chemotherapy and 14% with chemotherapy.
In conclusion, first-line Nivolumab plus chemotherapy has improved progression-free survival versus chemotherapy in patients with advanced NSCLC and less than 1% tumor PD-L1 expression, and was well tolerated.
Results are encouraging in this analysis, which includes only patients with less than 1% PD-L1.
CheckMate 227 Part 2 ( ongoing ) is evaluating Nivolumab plus chemotherapy vs chemotherapy irrespective of PD-L1 expression. ( Xagena )
Source: American Society of Clinical Oncology - ASCO Meeting, 2018
Primary analysis of CITYSCAPE study of the anti-TIGIT antibody Tiragolumab plus Atezolizumab versus Atezolizumab as first-line treatment in patients with PD-L1-selected NSCLC
The immunomodulatory receptor TIGIT is a novel inhibitory immune checkpoint present on activated T cells and NK cells in multiple...
Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer: results from GEOMETRY mono-1 study
In the ongoing, multicohort, phase 2 GEOMETRY mono-1 study, Capmatinib ( Tabrecta ) has shown efficacy in METex14–mutated non–small cell...
Hyperprogressive disease in advanced non–small cell lung cancer patients treated with immune checkpoint inhibitors
Hyperprogressive disease ( HPD ) is a paradoxical boost in tumour growth described in a subset of cancer patients treated...
Pembrolizumab in combination with chemotherapy has improved overall survival versus chemotherapy alone as first-line treatment for patients with advanced NSCLC whose tumors do not express PD-L1
The first-line treatment with Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with chemotherapy has demonstrated improvements in overall...
FDA has warned about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer
The FDA ( U.S. Food and Drug Administration ) has warned that Ibrance ( Palbociclib ), Kisqali ( Ribociclib ),...
The European Commission has granted marketing authorization in the European Union ( EU ) for the precision oncology treatment Vitrakvi...
Keytruda as first-line treatment for metastatic or unresectable recurrent head and neck squamous cell carcinoma: two new regimens approved by European Commission
The European Commission ( EC ) has approved Keytruda , an anti-PD-1 therapy, as monotherapy or in combination with Platinum...
Ibrance: FDA has expanded approved use of metastatic breast cancer treatment to include male patients
The FDA ( U.S. Food and Drug Administration ) has extended the indication of Ibrance ( Palbociclib ) capsules in...
FDA has approved Piqray, the first PI3K inhibitor for HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer
The FDA ( U.S. Food and Drug Administration ) has approved Piqray ( Alpelisib ) tablets, to be used in...
Lorviqua for treatment of adult patients with ALK-positive advanced non-small cell lung cancer, previously treated with one or more ALK tyrosine kinase inhibitors: approved in European Union
The European Commission ( EC ) has granted conditional marketing authorization for Lorviqua ( Lorlatinib, available in the U.S., Canada...